Affirm Holdings Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Affirm Holdings Inc trades at $77.35 (market cap $25.69B), while Alnylam Pharmaceuticals, Inc. trades at $221.5 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Affirm Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| AFRM | ALNY | |
|---|---|---|
Market Cap | $25.69B | $29.60B |
Sector | Financials | Health |
52-Week High | $92.18 | $491.22 |
52-Week Low | $42.53 | $205.48 |
Enterprise Value | $32.30B | $27.56B |
Trailing returns across standard periods
Latest headlines on both assets
Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.
Read more on AFRM →Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →